Home > Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma
Dermatological Cancer

Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma

Published Online: November 15th 2018

In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma.


1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European approval of encoranefib plus binimetanib for BRAF-mutant metastatic melanoma? (0:11)

2. What are the advantages of this combination compared with other combined BRAF/MEK inhibitor therapies? (1:25)

3. What are the best treatment options for patients whose disease progresses on this therapy? (2:41)

4. How can we prevent or overcome resistance to BRAF/MEK inhibitors? (3.18)

5. How is the approval of this combined therapy likely to impact on clinical practice? (4:24)

Speaker disclosures: Dirk Schadendorf has nothing to disclose in relation to this interview.

Filmed at the European Society for Medical Oncology (ESMO) congress, Germany, 19–23 October 2018

Share this Video
Related Videos In Dermatological Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar